Abstract:Objectives Stem cell therapy is a potential option for treating myocardial infarction. However, the effect is not as well as we expected. As a matter of fact, cell therapy is faced a lot of challenges, such as poor survival of the transplanted cells in the infracted region, low number of cells migrated into myocardial lesions, and so on. So the aim of this study is to explore a new strategy that angiotensin receptor type 2 stimulation can improve the engraftment of bone marrow mononuclear cells in the infracted myocardium and recover heart function. Methods Mononuclear cells (MNCs), isolated from SD rat bone marrow, were treated with several reagents which can change the activity of AT2R of MNCs. The experiment group designation for in vitro study were: MNCs (control), MNCs+AngII, MNCs+CGP42112A, MNCs+AngII+ARB, MNCs+AngII+PD123319 and MNCs+CGP+ARB. The ability of migration and cardioprotection were examined by tran-swell and co-culturing with neonatal cardiomyocytes. The experiment group designation for in vivo study were: DMEM, MNCs, MNCs+CGP42112A and MNCs+AngII+ARB. Cells from different groups were intramyocardially injected into the peri-infarct region. Inflammatory cytokine expression, death of cardiomyocyte, anti-apoptotic protein expression were assessed 3 days after transplantation. Meanwhile we transplant above-mentioned female rats'cells into male rats via tail vein, and evaluate the number of engrafted cells 1 day after transplantation by real-time PCR. Infarct size, angiogenesis and heart function were measured 1 month after transplantation. Results Bone marrow mononuclear cells, when their AT2R were stimulated, can prevent neonatal cardiomyocytes from apoptosis in vitro. Also more cells migrated into low chamber in same situation. Transplantation of AT2R-activated bone marrow cells intramyocardially after myocardial infarction resulted in decrease in inflammatory cytokines (IL-1, IL-6, MCP-1) expression, death rate of cardiomyocytes in peri-infarcted region, as well as increase in anti-apoptotic protein expression (Bcl2). Also more bone marrow mononuclear cells were found in myocardial lesions 1 d after transplantation via tail vein. No matter which transplanted routes we choose, transplantation of AT2R-activated bone marrow cells can improve heart function significantly. Conclusions Angiotensin receptor type 2 stimulation can increase the migration of bone-marrow mononuclear cells into the infracted myocardium and prevent cardiomyocytes from apoptosis, thus activate AT2R of bone marrow stem cells maybe a novel option for enhancing benefits of stem cell therapy.

Priming with angiopoietin-1 augments the vasculogenic potential of the peripheral blood stem cells mobilized with granulocyte colony-stimulating factor through a novel Tie2/Ets-1 pathway

Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor.

Therapeutic Angiogenesis of Bone Marrow Mononuclear Cells (mncs) and Peripheral Blood Mncs: Transplantation for Ischemic Hindlimb

Angiopoietin-1 Preconditioning Enhances Survival and Functional Recovery of Mesenchymal Stem Cell Transplantation

Combination of Stromal-Derived Factor-1Α and Vascular Endothelial Growth Factor Gene-Modified Endothelial Progenitor Cells is More Effective for Ischemic Neovascularization

Angiotensin Receptor Type 2 Stimulation Increases the Migration of Bone-Marrow Mononuclear Cells into the Infarcted Myocardium and Improves Heart Function

C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Angiogenic Potential of Bone Marrow Derived CD133+ and CD271+ Intramyocardial Stem Cell Trans- Plantation Post MI

Enhancement strategy for effective vascular regeneration following myocardial infarction through a dual stem cell approach

Regeneration-associated cells improve recovery from myocardial infarction through enhanced vasculogenesis, anti-inflammation, and cardiomyogenesis

A Combination of Distinct Vascular Stem/Progenitor Cells for Neovascularization and Ischemic Rescue.

Deterioration of cardiac function after acute myocardial infarction is prevented by transplantation of modified endothelial progenitor cells overexpressing endothelial NO synthases.

Pro-Angiogenic Actions of CMC-Derived Extracellular Vesicles Rely on Selective Packaging of Angiopoietin 1 and 2, but Not FGF-2 and VEGF

Enhancement of Neovascularization with Mobilized Blood Cells Transplantaion: Supply of Angioblasts and Angiogenic Cytokines

MicroRNA-326-5p Enhances Therapeutic Potential of Endothelial Progenitor Cells for Myocardial Infarction

Autologous transplantation of EPCs encoding FGF1 gene promotes neovascularization in a porcine model of chronic myocardial ischemia.

Bradykinin-pretreated Human Cardiac-Specific C-Kit + Cells Enhance Exosomal Mir-3059-5p and Promote Angiogenesis Against Hindlimb Ischemia in Mice

Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI

Role of HIF-1α-activated Epac1 on HSC-mediated neuroplasticity in stroke model

Allogeneic transplantation of programmable cells of monocytic origin (PCMO) improves angiogenesis and tissue recovery in critical limb ischemia (CLI): a translational approach

Novel cell therapy with ex vivo cultured peripheral blood mononuclear cells significantly impacts angiogenesis in the murine ischemic limb model